Randomized trial evaluates collagen stimulation effects in aesthetic medicine, highlighting novel injectable therapies.
a. Aims and Backgrounds Biostimulatory injectables represent a transformative paradigm in aesthetic medicine, shifting the therapeutic focus from immediate volumization to biologically driven tissue regeneration. Unlike traditional hyaluronic acid fillers, agents such as calcium hydroxylapatite (CaHA) and poly-L-lactic acid (PLLA) harness the body's endogenous regenerative capacity by activating fibroblasts and promoting neocollagenesis. This chapter reviews the scientific foundations, mechanisms of action, clinical applications, and evolving role of these two principal biostimulatory agents. b. Anatomy CaHA and PLLA exert their regenerative effects primarily within the dermis and subdermal connective tissue. Optimal outcomes require precise injection technique within the subdermal plane, and treatment zones include the face, neck, décolletage, and body. c. Technology CaHA microspheres provide immediate structural support while simultaneously functioning as a biologic scaffold for neocollagenesis. PLLA microparticles achieve their regenerative effect through gradual polymer hydrolysis and prolonged fibroblast stimulation, yielding cumulative and durable improvements across staged treatment sessions. d. Techniques Both PLLA and Hyperdilute CaHA formulations enable versatile treatment across multiple anatomic regions. Optimal outcomes depend on proper patient selection, appropriate dilution strategies, and precise injection technique within the subdermal plane. e. Post Operative Care Thorough patient counseling regarding the delayed onset of results is essential to managing expectations. PLLA in particular requires staged treatment sessions to achieve cumulative improvements. f. Conclusions and Clinical Relevance Together, CaHA and PLLA offer clinicians a sophisticated, biologically grounded complement to the broader injectable armamentarium, addressing the underlying structural causes of facial aging rather than solely masking their clinical manifestations.
No takes yet. Share an insight, caveat, or question.
Michael Somenek (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: